Please enable JavaScript to continue using this application.

Compare $ELDN vs $LYEL | Chartloom

Compare

$ELDN vs $LYEL

Eledon Pharmaceuticals Inc · Lyell Immunopharma Inc

ELDN

Eledon Pharmaceuticals Inc

LYEL

Lyell Immunopharma Inc

Compare $ELDN vs $LYEL

Comparing Eledon Pharmaceuticals Inc and Lyell Immunopharma Inc

ELDNEledon Pharmaceuticals Inc

LYELLyell Immunopharma Inc

ELDNEledon Pharmaceuticals Inc

Market cap

$191M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

53.1%

52W performance

-13.6%

FCF yield

-38.6%

LYELLyell Immunopharma Inc

Market cap

$203M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

16,911.71x

Rev growth (TTM)

-55.0%

YTD performance

-69.9%

52W performance

-52.3%

FCF yield

-86.2%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

ELDN

LYEL

Detailed metrics comparison

ELDN

Eledon Pharmaceuticals Inc

LYEL

Lyell Immunopharma Inc

Market Cap

ELDN$191M

LYEL$203M

Enterprise Value

ELDN$185M

LYEL$130M

Price

ELDN$2.48

LYEL$8.71

P/E Ratio

ELDNN/A

LYELN/A

P/S Ratio

ELDN0.00x

LYEL7,526.09x

EV/Sales

ELDN0.00x

LYEL4,822.94x

EV/EBITDA

ELDN0.00x

LYEL0.00x

P/B Ratio

ELDN2.81x

LYEL0.97x

P/FCF Ratio

ELDNN/A

LYELN/A

EV/FCF

ELDN-2.50x

LYEL-0.74x

PEG Ratio

ELDNN/A

LYELN/A

Forward P/E (NTM)

ELDNN/A

LYELN/A

Forward P/S (NTM)

ELDNN/A

LYEL16,911.71x

Revenue (TTM)

ELDN$0

LYEL$27K

Revenue Growth (YoY)

ELDNN/A

LYEL-55.0%

Forward Rev Growth

ELDN325.8%

LYEL7184.7%

Gross Margin (TTM)

ELDN0.0%

LYEL0.0%

Operating Margin (TTM)

ELDN0.0%

LYEL0.0%

EBITDA Margin (TTM)

ELDN0.0%

LYEL-669059.3%

Net Margin (TTM)

ELDN0.0%

LYEL-920285.2%

FCF Margin (TTM)

ELDNN/A

LYEL-648763.0%

Net Income (TTM)

ELDN$-99M

LYEL$-248M

FCF (TTM)

ELDN$-74M

LYEL$-175M

EPS (TTM)

ELDN-$0.87

LYEL-$10.64

ROE (TTM)

ELDN-9848.0%

LYEL-9162.0%

ROA (TTM)

ELDN-6897.0%

LYEL-7050.0%

ROIC (TTM)

ELDN-9848.0%

LYEL-9162.0%

Cash

ELDN$7M

LYEL$73M

Debt

ELDN$0

LYEL$0

Net Cash/Debt

ELDN$7M

LYEL$73M

Current Ratio (TTM)

ELDN7.90x

LYEL5.36x

Quick Ratio (TTM)

ELDN7.60x

LYEL5.12x

Debt/Equity (TTM)

ELDN0.00x

LYEL0.00x

Debt/Assets (TTM)

ELDN0.0%

LYEL0.0%

Interest Coverage (TTM)

ELDNN/A

LYELN/A

Net Debt/EBITDA (TTM)

ELDN0.00x

LYEL0.00x

Beta

ELDN1.01

LYEL-0.04

52W Performance

ELDN-13.6%

LYEL-52.3%

YTD Performance

ELDN53.1%

LYEL-69.9%

% from 52W High

ELDN-46.1%

LYEL-80.6%

% from 52W Low

ELDN83.7%

LYEL6.1%

Asset Turnover (TTM)

ELDN0.00x

LYEL0.00x

FCF Yield (TTM)

ELDN-38.6%

LYEL-86.2%

Earnings Yield (TTM)

ELDN-51.5%

LYEL-122.3%

Dividend Yield (TTM)

ELDNN/A

LYELN/A

Rule of 40

ELDN0.0

LYEL-648,818.0

EV/GP/RG

ELDNN/A

LYELN/A

Ticker research

View ELDN research View LYEL research

Metric	ELDN Eledon Pharmaceuticals Inc	LYEL Lyell Immunopharma Inc
Market & Valuation
Market Cap	$191M	$203M
Enterprise Value	$185M	$130M
Price	$2.48	$8.71
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	7,526.09x
EV/Sales	0.00x	4,822.94x
EV/EBITDA	0.00x	0.00x
P/B Ratio	2.81x	0.97x
P/FCF Ratio	N/A	N/A
EV/FCF	-2.50x	-0.74x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	16,911.71x
Revenue & Growth
Revenue (TTM)	$0	$27K
Revenue Growth (YoY)	N/A	-55.0%
Forward Rev Growth	325.8%	7184.7%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-669059.3%
Net Margin (TTM)	0.0%	-920285.2%
FCF Margin (TTM)	N/A	-648763.0%
Net Income (TTM)	$-99M	$-248M
FCF (TTM)	$-74M	$-175M
EPS (TTM)	-$0.87	-$10.64
ROE (TTM)	-9848.0%	-9162.0%
ROA (TTM)	-6897.0%	-7050.0%
ROIC (TTM)	-9848.0%	-9162.0%
Financial Health
Cash	$7M	$73M
Debt	$0	$0
Net Cash/Debt	$7M	$73M
Current Ratio (TTM)	7.90x	5.36x
Quick Ratio (TTM)	7.60x	5.12x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.01	-0.04
52W Performance	-13.6%	-52.3%
YTD Performance	53.1%	-69.9%
% from 52W High	-46.1%	-80.6%
% from 52W Low	83.7%	6.1%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.00x
FCF Yield (TTM)	-38.6%	-86.2%
Earnings Yield (TTM)	-51.5%	-122.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-648,818.0
EV/GP/RG	N/A	N/A
Ticker research	View ELDN research	View LYEL research

Valuation

P/S Ratio

ELDN

0.00x

LYEL

7,526.09x

EV/FCF

ELDN

-2.50x

LYEL

-0.74x

Growth & revenue

Revenue Growth TTM

LYEL

-55.0%

Forward Revenue Growth

LYEL

7184.7%

ELDN

325.8%

Profitability & performance

Gross Margin

ELDN

0.0%

LYEL

0.0%

ROE

LYEL

-9162.0%

ELDN

-9848.0%

FCF Yield %

ELDN

-38.6%

LYEL

-86.2%

52-Week Performance

ELDN

-13.6%

LYEL

-52.3%

Detailed metrics comparison

ELDN

Eledon Pharmaceuticals Inc

LYEL

Lyell Immunopharma Inc

Market Cap

ELDN$191M

LYEL$203M

Enterprise Value

ELDN$185M

LYEL$130M

Price

ELDN$2.48

LYEL$8.71

P/E Ratio

ELDNN/A

LYELN/A

P/S Ratio

ELDN0.00x

LYEL7,526.09x

EV/Sales

ELDN0.00x

LYEL4,822.94x

EV/EBITDA

ELDN0.00x

LYEL0.00x

P/B Ratio

ELDN2.81x

LYEL0.97x

P/FCF Ratio

ELDNN/A

LYELN/A

EV/FCF

ELDN-2.50x

LYEL-0.74x

PEG Ratio

ELDNN/A

LYELN/A

Forward P/E (NTM)

ELDNN/A

LYELN/A

Forward P/S (NTM)

ELDNN/A

LYEL16,911.71x

Revenue (TTM)

ELDN$0

LYEL$27K

Revenue Growth (YoY)

ELDNN/A

LYEL-55.0%

Forward Rev Growth

ELDN325.8%

LYEL7184.7%

Gross Margin (TTM)

ELDN0.0%

LYEL0.0%

Operating Margin (TTM)

ELDN0.0%

LYEL0.0%

EBITDA Margin (TTM)

ELDN0.0%

LYEL-669059.3%

Net Margin (TTM)

ELDN0.0%

LYEL-920285.2%

FCF Margin (TTM)

ELDNN/A

LYEL-648763.0%

Net Income (TTM)

ELDN$-99M

LYEL$-248M

FCF (TTM)

ELDN$-74M

LYEL$-175M

EPS (TTM)

ELDN-$0.87

LYEL-$10.64

ROE (TTM)

ELDN-9848.0%

LYEL-9162.0%

ROA (TTM)

ELDN-6897.0%

LYEL-7050.0%

ROIC (TTM)

ELDN-9848.0%

LYEL-9162.0%

Cash

ELDN$7M

LYEL$73M

Debt

ELDN$0

LYEL$0

Net Cash/Debt

ELDN$7M

LYEL$73M

Current Ratio (TTM)

ELDN7.90x

LYEL5.36x

Quick Ratio (TTM)

ELDN7.60x

LYEL5.12x

Debt/Equity (TTM)

ELDN0.00x

LYEL0.00x

Debt/Assets (TTM)

ELDN0.0%

LYEL0.0%

Interest Coverage (TTM)

ELDNN/A

LYELN/A

Net Debt/EBITDA (TTM)

ELDN0.00x

LYEL0.00x

Beta

ELDN1.01

LYEL-0.04

52W Performance

ELDN-13.6%

LYEL-52.3%

YTD Performance

ELDN53.1%

LYEL-69.9%

% from 52W High

ELDN-46.1%

LYEL-80.6%

% from 52W Low

ELDN83.7%

LYEL6.1%

Asset Turnover (TTM)

ELDN0.00x

LYEL0.00x

FCF Yield (TTM)

ELDN-38.6%

LYEL-86.2%

Earnings Yield (TTM)

ELDN-51.5%

LYEL-122.3%

Dividend Yield (TTM)

ELDNN/A

LYELN/A

Rule of 40

ELDN0.0

LYEL-648,818.0

EV/GP/RG

ELDNN/A

LYELN/A

Ticker research

View ELDN research View LYEL research

Metric	ELDN Eledon Pharmaceuticals Inc	LYEL Lyell Immunopharma Inc
Market & Valuation
Market Cap	$191M	$203M
Enterprise Value	$185M	$130M
Price	$2.48	$8.71
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	7,526.09x
EV/Sales	0.00x	4,822.94x
EV/EBITDA	0.00x	0.00x
P/B Ratio	2.81x	0.97x
P/FCF Ratio	N/A	N/A
EV/FCF	-2.50x	-0.74x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	16,911.71x
Revenue & Growth
Revenue (TTM)	$0	$27K
Revenue Growth (YoY)	N/A	-55.0%
Forward Rev Growth	325.8%	7184.7%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-669059.3%
Net Margin (TTM)	0.0%	-920285.2%
FCF Margin (TTM)	N/A	-648763.0%
Net Income (TTM)	$-99M	$-248M
FCF (TTM)	$-74M	$-175M
EPS (TTM)	-$0.87	-$10.64
ROE (TTM)	-9848.0%	-9162.0%
ROA (TTM)	-6897.0%	-7050.0%
ROIC (TTM)	-9848.0%	-9162.0%
Financial Health
Cash	$7M	$73M
Debt	$0	$0
Net Cash/Debt	$7M	$73M
Current Ratio (TTM)	7.90x	5.36x
Quick Ratio (TTM)	7.60x	5.12x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.01	-0.04
52W Performance	-13.6%	-52.3%
YTD Performance	53.1%	-69.9%
% from 52W High	-46.1%	-80.6%
% from 52W Low	83.7%	6.1%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.00x
FCF Yield (TTM)	-38.6%	-86.2%
Earnings Yield (TTM)	-51.5%	-122.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-648,818.0
EV/GP/RG	N/A	N/A
Ticker research	View ELDN research	View LYEL research